Drug Trial Radar · NCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Feb 6, 2023
Primary completion
Nov 28, 2023
Study completion Nov 28, 2023
Sponsor
- Lead sponsor
- MingSight Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Shenzhen MingSight Relin Pharmaceutical Co., Ltd
- First posted
- Feb 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, single-arm, multicenter, open-label study which is divided into two portions: Phase I is dose escalation portion, in which subjects with relapsed or refractory B-cell lymphoma will be enrolled except malignant lymphoblastic lymphoma (LBL) and Burkitt lymphoma. After the RP2D is identified, Phase II of subjects with relapsed or refractory mantle cell lymphoma who previously received ≥ 2 and ≤ 4 different chemotherapy and/or targeted drug therapy will be enrolled.
Conditions
- Relapsed or Refractory B-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Marginal Zone Lymphoma (MZL)
Interventions
MS-553Drug
MS-553 oral tablet BID x 28-days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicity (DLT)Time frame: First cycle (28 days)
- Incidence and severity of adverse eventsTime frame: up to 24 months
- To determine the MTD and RP2D of oral MS-553 in patients with BCLTime frame: about 8 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.